|
Characteristics
|
No. of Patients (%)
|
|---|
|
Age, years
|
|
Median
|
62
|
|
Range
|
30–72
|
|
Sex
|
|
Male
|
4 (17)
|
|
Female
|
20 (83)
|
|
Race
|
|
White
|
22 (90)
|
|
Black
|
0
|
|
Other
|
2 (10)
|
|
ECOG performance status
|
|
ECOG 0
|
16 (67)
|
|
ECOG 1
|
7 (29)
|
|
ECOG 2
|
1 (4)
|
|
Tumor type
|
|
Ovarian/fallopian/peritoneal
|
10 (42)
|
|
Endometrial
|
5 (21)
|
|
Cervical
|
3 (13)
|
|
Esophageal
|
2 (8)
|
|
Urethral
|
1 (4)
|
|
Vaginal
|
1 (4)
|
|
Mesothelial
|
1 (4)
|
|
Salivary
|
1 (4)
|
|
Prior chemotherapiesa
|
|
0
|
7 (29)
|
|
1
|
1 (4)
|
|
2
|
7 (29)
|
|
3
|
9 (38)
|
-
ECOG Eastern Cooperative Oncology Group
-
aTherapies that included chemotherapy for radiation sensitization only (n = 4), were discontinued due to toxicity without progression (n = 2), were radiation alone (n = 4), or were hormonal only (n = 2) were not included for eligibility
